All In Biotech

Drug Trial Radar · NCT04702880

A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

A Randomized, Open-label Phase 2 Clinical Trial of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 135 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

135

Actual

Start

Mar 17, 2021

Primary completion

May 22, 2025

Study completion Nov 28, 2025

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jan 11, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to demonstrate that treatment with BMS-986012 in combination with carboplatin, etoposide, and nivolumab will have acceptable safety and tolerability and will improve progression-free survival compared with carboplatin, etoposide, and nivolumab alone in newly diagnosed participants with extensive-stage small cell lung cancer (ES-SCLC).

Conditions

  • Extensive-stage Small Cell Lung Cancer

Interventions

  • BMS-986012Biological

    Specified dose on specified days

  • CarboplatinDrug

    Specified dose on specified days

  • EtoposideDrug

    Specified dose on specified days

  • NivolumabBiological

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse EventsTime frame: From first dose to 100 days post last dose, or primary cutoff date, whichever occurs first (Up to approximately 43 months)
  2. Number of Participants With Serious Adverse EventsTime frame: From first dose to 100 days post last dose, or primary cutoff date, whichever occurs first (Up to approximately 43 months)
  3. Number of Participants With Adverse Events Leading to DiscontinuationTime frame: From first dose to 100 days post last dose, or primary cutoff date, whichever occurs first (Up to approximately 43 months)
  4. Number of Participants Who DiedTime frame: From first dose to primary cutoff date (Up to approximately 43 months)
  5. Progression Free Survival (PFS) Per Blinded Independent Central Review (BICR)Time frame: From randomization to the date of the first documented tumor progression, or death, or primary cutoff date, whichever occurs first (Up to approximately 50 months)

Locations

39 sites in 11 countries. Site status is shown where the registry gives one.

  • Local Institution - 0075

    Birmingham, Alabama

  • Local Institution - 0022

    Hackensack, New Jersey

  • Local Institution - 0002

    Durham, North Carolina

  • Local Institution - 0060

    Cincinnati, Ohio

  • Local Institution

    Cincinnati, Ohio

  • Local Institution - 0067

    Cleveland, Ohio

  • Local Institution - 0081

    Nashville, Tennessee

  • Local Institution

    Dallas, Texas

  • Local Institution - 0003

    Westmead, New South Wales, Australia

  • Local Institution - 0023

    Greenslopes, Queensland, Australia

  • Local Institution - 0001

    Malvern, Victoria, Australia

  • Local Institution - 0004

    Murdoch, Western Australia, Australia

  • Local Institution - 0034

    Ghent, Belgium

  • Local Institution - 0050

    Liège, Belgium

  • Local Institution - 0051

    Charleroi, Hainaut, Belgium

  • Local Institution - 0012

    Edmonton, Alberta, Canada

  • Local Institution - 0064

    Brampton, Ontario, Canada

  • Local Institution - 0036

    Athens, Greece

  • Local Institution - 0038

    Athens, Greece

  • Local Institution - 0045

    Heraklion, Irakleío, Greece

  • Local Institution - 0030

    Peschiera del Garda, Italy

  • Local Institution - 0031

    Pisa, Italy

  • Local Institution - 0029

    Rozzano, Italy

  • Local Institution - 0073

    Sendai, Miyagi, Japan

  • Local Institution - 0070

    Ōsaka-sayama, Osaka, Japan

  • Local Institution - 0069

    Takatsuki, Osaka, Japan

  • Local Institution - 0077

    Ina-machi, Saitama, Japan

  • Local Institution - 0066

    Arnhem, Netherlands

  • Local Institution - 0040

    Groningen, Netherlands

  • Local Institution - 0039

    Amsterdam, North Holland, Netherlands

  • Local Institution - 0049

    Gdansk, Poland

  • Local Institution - 0048

    Lodz, Poland

  • Local Institution - 0043

    Bucharest, Romania

  • Local Institution - 0042

    Cluj-Napoca, Romania

  • Local Institution - 0041

    Craiova, Romania

  • Local Institution - 0021

    Madrid, Spain

  • Local Institution - 0005

    Majadahonda, Spain

  • Local Institution - 0006

    Málaga, Spain

  • Local Institution - 0007

    Barcelona, Barcelona [Barcelona], Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.